PerkinElmer Appoints President, Life & Analytical Sciences
News Jan 27, 2006
PerkinElmer, Inc. has announced that Robert F. Friel has been named President of PerkinElmer's Life & Analytical Sciences (LAS) unit.
In this role, he will drive the strategic direction and growth of the $1.1-billion business, which focuses on providing applications-based solutions to customers in the genetic screening, biopharma and analytical sciences markets.
Friel will continue in the role of Vice Chairman of PerkinElmer, Inc., and remains a member of its Board of Directors.
Prior to being appointed Vice Chairman, Friel served as Executive Vice President and Chief Financial Officer of PerkinElmer, Inc.
He joined PerkinElmer in 1999 and was one of the primary architects of the Company's transformation into a global technology leader in health sciences and photonics.
Friel succeeds Peter B. Coggins, who will retire in February 2006, but will continue to support the Company as a senior advisor and consultant through mid-2007.
"Rob brings very broad commercial and operating experience, and a deep knowledge of PerkinElmer, to his new role leading Life & Analytical Sciences," said Gregory L. Summe, Chairman and Chief Executive Officer of PerkinElmer, Inc.
"He will continue to drive the business to the next level of customer, financial and operational excellence, taking advantage of the trends toward predictive diagnostics and personal therapeutics."
"We are also thankful for Peter's many significant contributions to the growth of LAS and pleased that we will continue to benefit from his strong market knowledge and technical expertise through mid-2007."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.